SYnAbs' mission is to generate innovative antibodies against poor immunogenic compounds (steroids, small molecules, carbohydrates, epigenetic modifications) and complex antigens (GPCR, ion channels, toxins, transporters, proteins from viral envelopes) thanks to unique technologies (DNA immunization, syngeneic cell immunization, rat-LOU species). Anti-drug antibodies, surrogates, or therapeutics mAbs one-stop-shop solution from antigen to gr manufacturing.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Rue Auguste Piccard 48, Charleroi,walloon Region 6041,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- synabs.be
- Keywords
- Custom generation of mAbs, High affinity mAbs, Highly specific mAbs, Guinea pig mAbs, Rat mAbs, Immuno-assay, Hybridoma development, Custom manufacturing, Monoclonal antibodies, Polyclonal antibodies, Antigen synthesis, Antibody purification, Immunoassay development.
- HQ
- Charleroi, Walloon Region
Synabs Questions
Synabs's website is synabs.be
Synabs's LinkedIn profile is https://be.linkedin.com/company/synabs
Synabs has
8 employees.
View email and phone details for 8
employees at Synabs.
Synabs's industry is
Biotechnology Research
Synabs's top competitors are
Hedera-22,
Amyl Therapeutics,
Novadip Biosciences S.a.,
Zentech S.a., Belgium,
Unizima,
Syngulon,
Contipharma,
Exothera,
Earth Alive Clean Technologies,
Catalent.
Synabs's categories are Biotechnology Research
Synabs's founding year is 2015
